Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Research runs each weekday at 8 a.m. Eastern Time. Channels update when qualifying developments are found. Editorial standards · RSS ↗
MRNA / LNP / RESEARCH LIBRARY
Important mRNA/LNP publications from the past 120 days
Search bilingual publication guides on delivery, in vivo CAR-T, therapeutic translation, safety, analytics, and manufacturing.
Researchers modified buffer exchange into a two-step dialysis process, first promoting fusion under acidic, higher-ionic-strength conditions while retaining ethanol, then removing ethanol and raising pH. Compared with one-step exchange, the process increased mRNA copies per particle, reduced empty particles, and improved transfection in cells and animals. These formulation-specific results do not establish that removing empties always improves every product.
Researchers incorporated an amphiphilic PD-L1 inhibitor as an additional nanoparticle component rather than administering it separately. The modified formulation increased lymph-node reporter expression and strengthened vaccine-associated immune responses in experimental models. Similar targeting effects were observed with two ionizable lipid backbones. These results suggest formulation-dependent immune targeting, without proving broad applicability or clinical benefit across tumor types.
Researchers compared 12 lyophilized mRNA-LNP formulations containing sucrose, trehalose, and polyvinylpyrrolidone. A ternary protectant system at a 1:20 lipid-to-protectant ratio preserved particle properties, RNA integrity, and in vitro transfection after one month at 40°C. Sucrose crystallization reduced protection. The results show why physical measurements need functional confirmation and do not establish a clinical product shelf life.
Heparosan surface modification was compared with conventional PEG-based nanoparticles across several ionizable lipid formulations. Modified particles improved expression in immune-cell models and showed reduced association with late endosomes and lysosomes. Mouse experiments assessed repeated expression and vaccine antibody responses. The findings support an alternative surface-engineering approach, while long-term immunogenicity, biodistribution, and manufacturing consistency require additional study.
Arcturus reported interim Phase 2 findings for ARCT-810 in ornithine transcarbamylase deficiency, including lower or maintained-normal fasting ammonia and reduced glutamine, with generally favorable tolerability. The company plans to incorporate next-generation ARCT-2601 into an amended protocol near year-end. Separately reported large expression gains for its new delivery platform came from nonhuman-primate studies, not comparative human efficacy data.
ExploRNA and the Łukasiewicz Industrial Chemistry Institute announced a partnership to advance GMP-quality manufacturing of proprietary mRNA cap analogs, including AvantCap Q1. The collaboration combines capping technology with chemical synthesis and production scale-up to support clinical-stage mRNA vaccines and therapeutics. The announcement did not disclose financial terms or establish that newly manufactured batches had already been delivered to customers.
Researchers reorganized preformed nanoparticles so a metabolic RNA becomes available before the therapeutic payload. This staged architecture increased cellular energy availability and subsequent protein production. Mouse cancer and infectious-disease vaccine experiments showed improved immune activity, supporting spatial organization as an additional delivery design variable. Compatibility across several nucleic acid formats was demonstrated, but human performance remains untested.
This review compares self-amplifying and circular RNA vaccine architectures, expression kinetics, delivery approaches, and immune responses. It discusses the different reasons these platforms may extend antigen production or reduce dose requirements, alongside manufacturing, purity, reactogenicity, and regulatory challenges. It is a synthesis of heterogeneous preclinical and early clinical evidence, not a new head-to-head trial establishing superiority over conventional mRNA vaccines.
NGK announced development of a ceramic-membrane device for lipid nanoparticle manufacturing. The concept adjusts membrane area and porosity to retain a common mixing principle across processing scales, addressing quality changes that can occur when manufacturers switch mixing technologies. NGK reported encouraging evaluation results, but the device remains under development; commercial-scale GMP validation was not established in the announcement.
Antibody-coated nanoparticles targeted TREM2-expressing tumor-associated macrophages and combined CXCL9-encoding mRNA with a Toll-like receptor agonist. The approach remodeled the tumor immune environment and increased cytotoxic T-cell infiltration and activity. Additional checkpoint blockade strengthened immune responses in experimental models. This is a targeted delivery and combination-immunotherapy proof of concept, rather than evidence of efficacy in patients.
Ethris signed a €30 million financing agreement with the European Investment Bank under HERA Invest to support respiratory mRNA medicines. Its development platform pairs stabilized mRNA with lipid nanoparticles designed for local respiratory delivery, with programs spanning respiratory disease and mucosal vaccines. The announcement describes bank financing, not an equity round or an unconditional grant, and does not establish clinical success.
Using yeast RNA as a model payload, researchers evaluated atomization, freezing, drying temperature, and annealing during spray-freeze drying of RNA-LNPs. Powder diffraction, microscopy, and solid-state NMR supported characterization. Sucrose outperformed trehalose in the tested systems, and annealing improved stability. Because the payload was model RNA, these findings do not directly establish therapeutic mRNA expression potency or clinical-product stability.
Continue your research
Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.
